First Time Loading...

Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 994 GBX 0.66% Market Closed
Updated: May 12, 2024

Hikma Pharmaceuticals PLC
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hikma Pharmaceuticals PLC
Operating Income Peer Comparison

Comparables:
GSK
AZN
VRNA
INDV
DPH

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Hikma Pharmaceuticals PLC
LSE:HIK
Operating Income
$622m
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
6%
GlaxoSmithKline PLC
LSE:GSK
Operating Income
£7.3B
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
1%
AstraZeneca PLC
LSE:AZN
Operating Income
$8.6B
CAGR 3-Years
27%
CAGR 5-Years
14%
CAGR 10-Years
11%
Verona Pharma PLC
NASDAQ:VRNA
Operating Income
-$67.6m
CAGR 3-Years
3%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Operating Income
$257m
CAGR 3-Years
20%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Operating Income
£24.9m
CAGR 3-Years
-25%
CAGR 5-Years
-11%
CAGR 10-Years
3%

See Also

What is Hikma Pharmaceuticals PLC's Operating Income?
Operating Income
622m USD

Based on the financial report for Dec 31, 2023, Hikma Pharmaceuticals PLC's Operating Income amounts to 622m USD.

What is Hikma Pharmaceuticals PLC's Operating Income growth rate?
Operating Income CAGR 10Y
6%

Over the last year, the Operating Income growth was 22%. The average annual Operating Income growth rates for Hikma Pharmaceuticals PLC have been 6% over the past three years , 7% over the past five years , and 6% over the past ten years .